[HTML][HTML] Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives
The choice of drugs is based on their efficacy and toxicity. Based on this principle, the 2008
and then the 2011 WHO guidelines proposed a range of five groups, from group 1 (which …
and then the 2011 WHO guidelines proposed a range of five groups, from group 1 (which …
An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT study)
Rationale: Improving treatment outcomes while reducing drug toxicity and shortening the
treatment duration to∼ 6 months remains an aspirational goal for the treatment of multidrug …
treatment duration to∼ 6 months remains an aspirational goal for the treatment of multidrug …
Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis
R Gupta, LJ Geiter, J Hafkin… - The International Journal …, 2015 - ingentaconnect.com
2 Evans TB, Mador MJ, Glick M, Ahmad I. Tuberculosis misclassification among resettled
refugees in Buffalo, New York, USA. Int J Tuberc Lung Dis 2015; 19: 231–236. 3 Centers for …
refugees in Buffalo, New York, USA. Int J Tuberc Lung Dis 2015; 19: 231–236. 3 Centers for …
Clinical implications of new drugs and regimens for the treatment of drug-resistant tuberculosis
YS Kwon - Chonnam Medical Journal, 2017 - synapse.koreamed.org
The emergence of drug-resistant tuberculosis (TB) is a growing problem worldwide. The lack
of safe and effective drugs, together with the frequent development of adverse drug …
of safe and effective drugs, together with the frequent development of adverse drug …
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
About 1· 3 million people died of tuberculosis in 2012, despite availability of effective drug
treatment. Barriers to improvements in outcomes include long treatment duration (resulting …
treatment. Barriers to improvements in outcomes include long treatment duration (resulting …
Extensively drug-resistant tuberculosis: epidemiology and management
A Matteelli, A Roggi, ACC Carvalho - Clinical epidemiology, 2014 - Taylor & Francis
The advent of antibiotics for the treatment of tuberculosis (TB) represented a major
breakthrough in the fight against the disease. However, since its first use, antibiotic therapy …
breakthrough in the fight against the disease. However, since its first use, antibiotic therapy …
Bedaquiline and delamanid in tuberculosis
S Esposito, S Bianchini, F Blasi - Expert opinion on …, 2015 - Taylor & Francis
Introduction: In recent years, a pressing need to develop new, effective and safe drugs
against tuberculosis (TB) has continued. Poor adherence to a long therapeutic regimen …
against tuberculosis (TB) has continued. Poor adherence to a long therapeutic regimen …
Tuberculosis treatment and drug regimens
G Sotgiu, R Centis… - Cold Spring …, 2015 - perspectivesinmedicine.cshlp.org
Tuberculosis is an airborne infectious disease treated with combination therapeutic
regimens. Adherence to long-term antituberculosis therapy is crucial for maintaining …
regimens. Adherence to long-term antituberculosis therapy is crucial for maintaining …
World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
D Falzon, HJ Schünemann, E Harausz… - European …, 2017 - Eur Respiratory Soc
Antimicrobial resistance is a major global concern. Tuberculosis (TB) strains resistant to
rifampicin and other TB medicines challenge patient survival and public health. The World …
rifampicin and other TB medicines challenge patient survival and public health. The World …
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update
Antimicrobial resistance is a major public health problem globally. Likewise, forms of
tuberculosis (TB) resistant to first-and second-line TB medicines present a major challenge …
tuberculosis (TB) resistant to first-and second-line TB medicines present a major challenge …